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Abstract: Conventional methods to analyze genome-wide association studies and whole exome 
or whole genome sequencing studies would be prone to overlook variants which might exert 
a recessive effect on risk of disease, either as homozygotes or compound heterozygotes. It is 
plausible that such effects may be common even in outbred populations. An approach is described 
which is based on identifying a set of variants in a gene as being potentially of interest and then 
testing whether there is an excess of cases who are either homozygotes or complex heterozygotes 
for these variants. Methods based on departure from Hardy–Weinberg equilibrium are more 
powerful than those which compare cases to controls. However, linkage disequilibrium between 
variants can be difficult to deal with if phase is unknown. A simple approach for discarding 
variants apparently in strong linkage disequilibrium with others is proposed. The procedure is 
simple and quick to apply so can be used in the context of whole genome or exome sequencing 
studies and is implemented in the SCOREASSOC program.
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Introduction
As discussed elsewhere in the context of schizophrenia,1 it is entirely plausible that 
recessive effects might make a substantial contribution to susceptibility to disease in 
outbred populations but would not be detected by standard approaches to the analysis of 
genome-wide association studies (GWASs), single-nucleotide polymorphisms (SNPs) 
or next generation sequencing data. Although standard methods typically assume 
dominant or additive effects, an argument can be made that in terms of biological 
function one might well expect that random genetic variation would be more likely to 
act recessively. It is worth restating some of the arguments in favor of this view.
If a randomly occurring variant in a gene has an effect then it is likely to lead to 
a product which functions less well than the wild type. If a subject has two copies of 
the gene and the other is normal, then the usual outcome would be that there might 
be some overall lack of functioning due to a gene-dosage effect. Only rarely might a 
more specific mechanism produce a more dominantly acting effect; for example, by 
leading to an abnormal product which in some way interferes with the functioning of 
the normal product or is pathogenic through some other mechanism. Likewise, one 
might expect that it would be rare for a random variation to produce a gain of function. 
On the other hand, if both copies of the gene were abnormal, then one could readily 
arrive at a situation where there was marked or complete loss of function overall.
Another reason for suspecting that recessive effects may be common is through 
consideration of the effects of selection, which will be far weaker for recessive than 
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dominant variants. To take the most extreme example, a domi-
nantly acting variant which is lethal in youth will undergo 
complete selection and by definition can only arise through 
de-novo mutation. By contrast, variants which are lethal in 
homozygotes can persist in the population at relatively high 
frequency, and there are countless Mendelian recessive dis-
orders which illustrate this. For recessively acting variants 
which increase susceptibility to disease without necessarily 
completely compromising reproductive fitness, selection 
pressures will exert even less effect on allele frequency. 
Recessive X-linked disorders represent an intermediate 
situation where selection occurs primarily through males. 
(Though there may be some secondary effects on female 
reproductive fitness; for example, if caring for an affected 
son impairs the ability to produce further children or if fam-
ily stigma makes it more difficult for carrier sisters to marry 
and have children.)
If we acknowledge that there are a priori reasons to 
suspect that recessive effects might be common, we should 
go on to point out that many would have been overlooked 
by standard analytic methods. While there are examples of 
recessive mutations which have been detected in sequencing 
studies2,3 it can be argued that standard approaches applied 
to outbred populations might overlook variants making an 
important contribution to risk, especially if they involved 
variants which were not very obviously damaging and/or 
formed compound heterozygotes. Before proceeding to 
discuss compound heterozygotes, we will first consider the 
simple situation where subjects homozygous for a single 
variant have increased risk of disease. With a Mendelian 
effect and no heterogeneity, all affected subjects would be 
homozygotes, but for more complex diseases, one would 
expect that only a proportion of cases would be homozygous 
for a given variant, since others would be due to the effects 
of other variants in the same gene, in different genes, or 
through other risk factors. There would thus be an increase 
in the number of cases homozygous for the risk variant, and 
there would be some increase in the overall frequency of 
this allele among cases, but this might be fairly modest. If 
one tested for it explicitly and if the variant were genotyped 
directly, then one could observe the excess of homozygotes, 
but in the context of a GWAS it is possible that tagging 
SNPs would not pick this up through being in incomplete 
linkage disequilibrium with the causal variant and/or through 
having a higher allele frequency. Thus, there might not be 
a marked tendency for the tagging SNPs themselves to be 
homozygous more frequently in cases than controls. In the 
context of a sequencing study, the excess of homozygotes 
would be  apparent if it was looked for specifically but might 
well be missed if a simple burden test was performed. It is 
also important to point out that recessively acting variants 
tend to have higher allele frequencies than dominant ones and 
hence they might well be overlooked in a sequencing study 
that tends to focus attention only on very rare variants.
The situation becomes more complex if we consider the 
possibility of different variants forming compound heterozy-
gotes to produce a joint recessive effect on pathogenesis. This 
might well be a common situation, especially because such 
variants would be subjected to little in the way of selection 
pressure. If there were several different variants which could 
act together in this way then they could well be overlooked 
completely. In the context of a GWAS, each might be in 
linkage disequilibrium (LD) with different combinations 
of tagging SNPs, rendering it virtually impossible to detect 
the influence of any of them. In a sequencing study there 
would be only a modest increase in the frequency of each 
variant, and indeed of all variants combined. There would be 
expected to be some increase in homozygotes among cases, 
but in fact compound heterozygotes would occur more often 
than homozygotes, and any method which considered each 
variant individually, without evaluating the extent to which 
different variants co-occurred in the same subject, would 
have marked loss of power. The magnitude of these effects 
was quantified using a range of simple models.1 To take one 
of these examples, we can consider a disease which has a 
population prevalence of 1%, with 5% of these cases being 
due to combinations of rare variants in a single gene acting 
recessively. If we assume that there are many rare variants in 
the gene but that only 25% of these have a pathogenic effect 
such as to increase the risk of disease to 0.2 if they occur as 
homozygotes or compound heterozygotes then a standard 
burden test will have power of only 3% to detect association 
at p = 10−6 with a sample size of 2000.1 However, if a test is 
performed to specifically detect an excess of cases possess-
ing at least two variants (either homozygotes or compound 
heterozygotes), then the power increases to 26%.
This paper explores some of the issues around developing 




Methods to detect an excess of homozygotes for a single 
variant are relatively straightforward. However, it is worth 
reiterating a point made elsewhere, which is that the test for 
an excess of homozygotes against the expectation under 
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Hardy–Weinberg Equilibrium (HWE) is far more powerful 
than the test for an excess of homozygotes among cases 
against controls.1 To take the example described above, the 
power to detect an excess of homozygotes against cases and 
controls is 26%, but the power to detect excess homozygotes 
among cases compared with the number expected under 
HWE is 72%.1 Similar substantial gains of power were found 
across a range of different recessive transmission models. An 
additional practical advantage of testing for departure from 
HWE is that one does not in fact need the control genotypes. 
One can simply use allele frequencies from the cases and 
controls to get a combined estimate of allele frequency and 
hence to determine the expected number of homozygous 
cases. If control allele frequencies are not available, then 
one can simply test for departure from HWE among cases. 
The appropriate test to use is a simple binomial test, which 
can be approximated by a Chi-squared test with one degree 
of freedom if expected counts are not too small.
While tests for departure from HWE are more power-
ful, they may be more susceptible to technical artefacts 
if homozygote and heterozygote calls cannot be reliably 
distinguished. This is not necessarily a major problem for 
comparisons of homozygote frequencies between cases and 
controls if there is no expectation that incorrect calls will be 
more frequent among cases.
In order for tests for departure from HWE to be valid, the 
assumptions underlying the expectation of HWE also need 
to be valid – essentially that the genotypes are drawn from 
a homogeneous sample in which random mating occurs. If 
these assumptions are violated to a substantial degree then 
observed departures from HWE might not necessarily provide 
evidence for recessive effects.
Selection of multiple variants
If we wish to consider multiple variants jointly then we will 
be testing the hypothesis that some subset of these variants 
impair the functioning of the gene and hence can act reces-
sively and increase risk of disease when one occurs as a 
homozygote or when two occur in trans to form a compound 
heterozygote.
There are a few topics which need to be addressed regard-
ing which variants should be included in such an analysis. 
Firstly, one needs to define a region of interest. As a start-
ing point, one might say that the unit of analysis should be 
a gene, but precisely what is meant by that would require 
some clarification.4 For example, if we are considering only 
recessive effects, it would make sense to say that we would 
only be interested in pairs of variants which both damage 
the same transcript and pairs which did not fulfill this condi-
tion would be irrelevant. One needs to consider the extent 
to which one would or would not include promoter regions 
and untranslated regions. One would also need to consider 
what types of variants to include. If the general approach 
will be to test whether there is an excess of cases possessing 
two or more variants then one needs to define which vari-
ants to include in a way which will mean that this condition 
would be met for only a small proportion of subjects under 
the null hypothesis, perhaps 10% or fewer. Thus, one could 
not include in the analysis very large numbers of variants or 
variants with a high minor allele frequency (MAF) because 
then all or nearly all subjects would possess at least two of 
them. In terms of function, one would probably not want to 
include synonymous or intronic variants. Although one would 
not want to include variants with high MAF, it is important 
to realize that variants having a recessive effect may have 
a considerably higher MAF than those with a dominant 
effect, and so the typical thresholds applied when searching 
for dominantly acting variants would not be appropriate. 
Certainly, one should not confine one’s attention to only 
“novel” or extremely rare variants. The exact threshold cho-
sen might depend on the specific circumstances, but a critical 
value of MAF ,0.1 might be appropriate for situations where 
one is dealing with a relatively common disease (prevalence 
around 1%). If the homozygote had a penetrance of 0.1, then 
cases due to homozygotes of this variant would then have 
prevalence of 0.1%. Overall, we would want to select a set 
of variants based on position, function, and MAF such that 
10% or fewer of subjects would be expected by chance to 
carry two or more variants.
Detecting an excess of homozygotes 
across multiple variants
It is straightforward to carry out a simple 2 × 2 Chi-squared 
analysis to see if cases are more frequently homozygous for 
at least one of the variants than controls.
However an alternative approach is to test for departure 
from HWE in cases. As noted above, this is more powerful 
than comparing the cases with controls. To derive a test sta-
tistic for this, we will begin by making the simplifying but 
usually false assumption that no LD exists between variants. 
Then, if we write p
i
 for the MAF of variant i, the probability 
for a case to be homozygous at this variant is p
i
2, and the 
probability to be homozygous for one or more variants is 
e
HOM
 = 1 − Π (1 − p
i
2). The MAF can be estimated jointly 
from cases and controls if available or if necessary only from 
cases. The observed number of cases who are homozygous 
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using a binomial test or, if the expected number is more 
than 5, a Chi-squared test. If the assumption of independence 
is violated, and LD is in fact present between variants, then 
the effect is to make this test more conservative. This is 
because if two variants tend to occur together, there is less 
opportunity for them to independently form homozygotes, 
and so the overall null hypothesis probability for a subject to 
be homozygous for at least one variant is reduced.
Detecting an excess of homozygotes  
and compound heterozygotes
It should be pointed out that there may be considerable 
benefits in attempting to detect an excess of compound 
heterozygotes rather than only homozygotes. Compound 
heterozygotes are expected to occur more frequently than 
homozygotes, especially when variants are individually 
rare. If we consider two rare variants each with MAF p, 
then the population frequency for either homozygote is p2, 
producing an overall frequency of 2p2 for homozygotes, but 
the frequency for compound heterozygotes is 4p2(1 − p)2. 
(We are ignoring all situations in which a subject has more 
than two variant alleles.) Thus, we could expect that there 
will be twice as many compound heterozygotes as there 
are homozygotes. This effect becomes stronger with larger 
numbers of variants.
Once again, it is straightforward to compare the counts 
between cases and controls of subjects carrying two or more 
of a set of variants. Although such a test remains valid if LD 
is present between variants (assuming it occurs to the same 
extent in both groups), LD can render the test problematic 
if it means that two variants frequently occur together and 
hence large numbers of subjects possess the same pair of 
variants. If a large proportion of controls carry at least two 
variants, then it becomes difficult or impossible to detect any 
excess among cases. Approaches to dealing with LD between 
variants will be discussed subsequently.
If for now we again make the assumption that there is no 
LD between variants, then we can derive the null hypothesis 
probability under HWE that a case will carry at least two 
 variants. This is best approached iteratively by considering 
each variant in turn and obtaining the cumulative prob-
abilities of a subject to have 0, 1, or more variants by the 
time we have included the ith variant. We will denote these 
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first variant we write:
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That is, for each new variant considered we take the prob-
abilities that it increases the overall variant count from 0, 1 
or more by 0, 1 or 2, so that for the ith variant we write:
 pAA
i





















i − 1 + 2(1 − pi)pi ⋅ pABi – 1 + (1 − pi)
2 ⋅ pBB
i − 1
As before, we can now use a binomial or Chi-squared test to 
compare the observed number of cases carrying two or more 





Of course, if an overall excess of cases with two or 
more variants is detected, then it may not be obvious which 
particular variants are pathogenic. Once one had established 
the general effect, one might seek to identify which variants 
were driving it, but potentially there might be a large number 
of variants and pairs of variants to select from.
Dealing with linkage disequilibrium 
between variants
Some preliminary investigation on real, though unpublished, 
datasets has revealed that it is by no means uncommon to 
find that variants within a gene can be in strong LD with 
each other. This can be observed even for variants which are 
extremely rare. The mechanisms which produce LD in such 
circumstances are not clear, because it might be assumed that 
it would be quite unlikely for one extremely rare variant to 
occur on the background of another. If LD between variants 
is not handled in some way, then the test for an excess of two 
or more variants based on HWE becomes completely invalid. 
If a pair of variants always occurs together because of LD, 
then if each subject possessing them is wrongly counted as a 
compound heterozygote, it would obviously produce a total 
number of subjects carrying two or more variants far higher 
than the expectation under independence outlined above.
The ideal solution to this problem would be if the sequenc-
ing method reported whether two variants were in cis or trans 
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and then only pairs of variants in trans would be counted as 
compound heterozygotes. If such information is not available, 
there are some statistical approaches which can be applied 
so that phase-unknown genotypes can be analyzed, albeit 
with some caveats.
The conventional approach to deal with this situation 
would be to use measures of LD or formal haplotyping 
algorithms to identify pairs of variants in LD with each 
other and then to remove one member until left with a set 
of independent variants. However, there are problems in 
applying these conventional approaches to the kind of data 
produced by sequencing studies because one has to deal 
with large numbers of variants, some of which are extremely 
rare. With typical sample sizes, there may be the situation 
where a subject carries two variants, neither of which is seen 
in any other subject. These would have a D′ of 1, and any 
maximum likelihood method would assign them to the same 
haplotype and hence one of the pair would be discarded. 
If this approach was followed, one could end up wrongly 
ignoring many pairs of variants which did in fact represent 
compound heterozygotes. One might take the approach of 
attempting to estimate LD relationships only from control 
subjects, but this could be problematic if there were many 
rare variants, and if a substantial proportion only occurred 
in cases.
Methods to phase rare variants are being developed,5 and 
as more sequence data becomes available then LD relation-
ships between variants will become better understood, and it 
may be possible to assign even quite rare variants to known 
haplotypes. For now, the question remains as to the best way 
to utilize data arising from sample sizes running into the 
hundreds or low thousands, and it does seem that the datasets 
themselves can provide some useful information. If there is 
an excess of cases carrying at least two variants, then there 
are a few characteristics of the genotypes which may support 
the hypothesis that these represent compound heterozygotes 
rather than alleles in LD with each other. These characteristics 
being as follows:
1.  If there is also an excess of homozygotes, then this is 
consistent with a recessive effect.
2.  If there is no excess of controls carrying at least two 
variants.
3.  If the variants observed to occur together also occur 
individually. If they occur in several subjects but always 
in the same pair, then this would suggest LD. If they 
sometimes occur together and sometimes not, then it can 
be difficult to determine whether they may be in LD to 
some extent.
4.  If pairs of different variants are not observed together as 
double homozygotes. If double homozygotes do occur, 
then the haplotype is defined and LD can be assumed to 
be present.
5.  If multiple different kinds of pairing are observed 
between different variants. If compound heterozygotes 
increase risk of disease, then we expect different pairs 
of variants to occur randomly among cases alongside 
homozygotes. However if we repeatedly observe 
the same pair, then we should suspect that LD is the 
explanation.
Although we can state these principles as being helpful 
to distinguish compound heterozygotes from variants in LD 
with each other, it is a challenge to incorporate them into a 
formal statistical test. At present there is no clear solution 
which is wholly satisfactory, although the situation is likely 
to improve in the future as more data are accumulated and 
more sophisticated statistical processes are developed.
For now, it is possible to propose a simple ad hoc 
approach, which is to discard a variant if it occurs more 
than once and if when it does occur there is one or more 
other variants which it “usually” occurs with. If quite a 
high value is chosen for “usually,” say 0.9 to only exclude 
pairs which almost always occur together, then there will 
be only a low risk of wrongly discarding any genes which 
might be of interest. For those genes which do then dem-
onstrate a statistically significant excess of cases carrying 
two or more variants, one can then examine the genotypes 
of these subjects more closely. At this point a number of 
factors may be brought in to attempt to decide whether the 
results are of interest. These factors will include not only 
the variant genotypes themselves but also the nature of the 
gene, the predicted effect, frequency and position of the 
variants, whether there is any evidence for dominant effects, 
and so forth.
To summarize, the proposed procedure to detect whether 
recessively acting variants may contribute to the effect of a 
gene on disease susceptibility is as follows:
1.  Define a region of interest; for example, all the exons of 
a gene or of one transcript, with or without untranslated 
regions, promoter regions, etc.
2.  Define which variants to include; for example, nonsense, 
missense, frame-shift coding and splice site variants hav-
ing MAF ,0.1. The aim should be that 10% or fewer 
controls will have two or more such variants.
3.  Eliminate any variants which show strong LD with 
another variant; for example, where the second variant 
occurs in 90% of subjects carrying the first variant.
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4.  Test whether the proportion of cases homozygous for at 
least one of these variants is larger than the proportion 
of controls.
5.  Test whether the proportion of cases homozygous for 
at least one variant is higher than would be expected 
assuming HWE. This finding will carry more weight if 
departure from HWE is not observed in controls.
6.  Test whether the proportion of cases carrying two or 
more variants, ie, homozygotes or possible compound 
heterozygotes, is higher than the proportion of controls.
7.  Test whether the proportion of cases carrying two or 
more variants is higher than would be expected under 
independence and HWE. Again, this finding will be more 
convincing if no excess is observed in controls.
This procedure has been implemented in the SCORE-
ASSOC program, which also implements a weighted 
burden test to detect dominantly acting effects.6 The tests 
are quick to perform and can readily be applied to exome-
wide or genome-wide next generation sequencing results 
on case control samples involving hundreds or thousands 
of subjects.
It is not expected that the application of this process in 
isolation will produce conclusive evidence that a particular 
gene is or is not involved in the etiology of a disease. Rather, 
it can be applied to whole genome data to focus attention on 
a small subset of genes which seem to provide some support 
for recessive effects. Then, these genes can be examined in 
more detail. This will involve consideration of the  plausibility 
of the gene, the observed pattern of variant genotypes, 
the predicted effects of the variants, whether there is also 
evidence that other variants in the gene produce dominant 
effects, and so forth.
Discussion
An approach for detecting recessively acting variants is 
outlined. It is emphasized that unless special steps are 
taken to test for such variants, they may well be overlooked 
by conventional approaches to analysis. The approach 
is based on considering multiple variants within a gene 
jointly. Statistical tests which detect departure from HWE 
are more powerful than those based on comparisons of 
cases and controls, but when compound heterozygotes 
are considered, they are very sensitive to LD between 
markers. Hence, it would be desirable to have a means to 
identify variants which are in trans rather than cis, but in 
the absence of this information, attempts can be made to 
detect LD from the distribution of variant genotypes and 
then to go on to discard variants which appear to be in 
strong LD with others. Application of such approaches may 
serve to focus attention on genes which might otherwise 
have been missed.
Although a test for departure from HWE in cases may 
be more powerful than testing for differences in genotype 
frequencies between cases and controls, this approach 
will only be valid if the variant alleles considered occur 
 independently. Departures from this assumption might be 
caused by LD or population stratification. It is natural to look 
to the control genotypes to assist in judging whether such 
confounding factors are relevant, but if one does this then 
one is essentially returning to a test which compares case and 
control genotypes. There is thus a tension between gaining 
power through making assumptions about the independence 
of variant alleles in cases and relinquishing some power 
through making fewer assumptions and simply comparing 
cases with controls.
It is perhaps worth pointing out that unfortunately follow-
ing up variants which potentially have a recessive effect may 
be more problematic than following up potential dominant 
variants. When recessive effects occur there may be a large 
number of variants which can combine to have a recessive 
effect on risk. If none tended to predominate, then when car-
rying out follow-up studies in additional samples one might 
need to carry out large numbers of genotyping assays to 
ensure that important effects were not missed.  Alternatively, 
it might be necessary to sequence relevant regions of the gene 
in order to characterize rare and novel variants. Likewise, 
functional studies might be more challenging as they would 
need to assess the effect of homozygous variants or two vari-
ants being present in trans.
It should also be pointed out that one unsatisfactory 
property of the proposed procedure is that it adopts an all 
or nothing approach to deciding which variants should be 
included in the analysis. It has been argued that schemes 
which weight variants according to rarity and functional 
effects are preferable to those which arbitrarily include some 
variants but not others, and methods have been developed 
which incorporate such weighting schemes for dominantly 
acting variants.6–9 However, it is not obvious how weighting 
methods should best be applied in the context of detecting 
recessive effects. An alternative to treating variants differ-
ently according to such factors as their rarity and predicted 
function would be to adopt a more post hoc, model-fitting 
approach which would attempt to make inferences about the 
nature and magnitude of the effect of each variant, though 
again it might be challenging to implement this in practice. 
Likewise, the proposal simply to discard some variants based 
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on apparent LD might not be optimal, and again it might be 
desirable to develop some scheme which could provide a 
more quantitative treatment.
It is hoped that if attention can be focused on this issue, 
then improved statistical and sequencing methods can be 
developed to more robustly characterize recessively acting 
variants, since they may make a substantial contribution to 
disease liability which would not be detected by methods 
which inherently focus on dominant effects.
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